Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

De la sencillez en el diagnóstico (no masivo) y seguimiento de la enfermedad hepática crónica avanzada a los complejos mecanismos terapéuticos de las estatinas en modelos animales.

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Ares Aurora Villagrasa Vilella, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/00947
Duration: 01/01/2019 - 30/06/2023

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEM APPROACHES

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 130472.5
Reference: DECISION_H2020-SC1-BHC2019
Duration: 01/04/2020 - 30/09/2025

Enfermedades hepáticas-Enfermedad crónica hepática avanzada y sus complicaciones.

IP: Joan Genescà Ferrer
Collaborators: Mònica Pons Delgado, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM18/00061
Duration: 01/01/2019 - 20/09/2021

EU Patient- cEntric clinicAl tRial pLatform - EU PEARL.

IP: Joan Genescà Ferrer
Collaborators: Santiago Pérez Hoyos, Anna Sanjuan Viaplana, Xavier Cañas Perea, Juan Espinosa Pereiro, Juan Manuel Pericàs Pulido, José Antonio Ramos Quiroga, Israel Molina Romero, Alex Sánchez Pla, Inmaculada Fuentes Camps, Adrián Sánchez Montalvá, Pol Ibañez Jimenez, Olga Sánchez- Maroto Carrizo, Gara Arteaga Henriquez, Sergio Gabriel Muñoz Martínez, Janna Anthonina Slabbekoorn, Albert Barberà LLuis
Funding agency: The Innovative Medicines Initiative
Funding: 1987375
Reference: EU-PEARL_H2020_IMI2-2018
Duration: 01/11/2019 - 30/04/2023

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Alba Estela García Fernández

Alba Estela García Fernández

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Veronica Estepa Calvo

Veronica Estepa Calvo

Research technician
Reconstructive Surgery of the Locomotor System
Read more
Zuleika del Carmen Gonzalez Ramos

Zuleika del Carmen Gonzalez Ramos

Predoctoral researcher
Multidisciplinary Nursing Research Group
Read more
Paula Fernández Álvarez

Paula Fernández Álvarez

Research technician
Genetics Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.